Cerevel Therapeutics Email Format
Pharmaceutical Manufacturing
・
50,001-100,000 employees
・
North Chicago, IL, USA
Cerevel Therapeutics is a neuroscience-focused biopharmaceutical company now part of AbbVie, dedicated to developing therapies for neurological and psychiatric disorders.
Search our verified sources for decision-makers, emails, and titles.
Start searching
VERIFIED BY CLAY
first.last@cerevel.com
Company Overview
Industry
Pharmaceutical Manufacturing
Founded
2018
Headquarters
North Chicago, IL, USA
Revenue
$50B-$100B
FUNDING Stage
Acquired
Website
Key Executives
Susan Altschuller, Ph.D., MBA (Chief Financial Officer), Paul Burgess (Chief Business Development and Strategic Operations Officer), Kaya Pai Panandiker (Head of Commercial)
Tech Stack
Key Executives
4.9/5 on G2
40K+ GTM professionals
SOC 2 Type II certified
Frequently Asked Questions
What is the email format of Cerevel Therapeutics?
Cerevel Therapeutics uses the first.last format, so Jane Smith would be jane.smith@cerevel.com.
What neurological conditions does Cerevel Therapeutics focus on with its pipeline?
Cerevel Therapeutics has built its pipeline around neurological and psychiatric conditions including Parkinson's disease, schizophrenia, epilepsy, and dementia-related apathy, with each program targeting specific receptor subtypes to reduce side effects common with older treatments.
How can I find and verify a Cerevel Therapeutics contact email for outreach?
Since Cerevel Therapeutics uses the first.last@cerevel.com format, you can build addresses directly from a contact's name and verify them using a tool like Clay, which cross-references multiple data sources to confirm deliverability before you send.
Where was Cerevel Therapeutics founded, and what is its origin story?
Cerevel Therapeutics was founded in 2018 in the Greater Boston area as a collaboration between Pfizer and Bain Capital, spinning out a set of CNS drug candidates from Pfizer with $350 million in initial funding to pursue selective neuroscience therapies.
Is tavapadon, the Cerevel Therapeutics Parkinson's drug, currently under FDA review?
Yes, AbbVie submitted a New Drug Application to the FDA for tavapadon in September 2025, backed by three Phase 3 trials. In 2026, new data presented at the American Academy of Neurology showed that roughly 90 percent of patients did not need levodopa initiation or dose increases after more than a year of treatment.
Get access to more people and company data using Clay
Leverage the power of 100+ data providers for industry-leading data coverage & quality.
4.9 rating